Get Mounjaro Online — From $179/Month

Mounjaro was the first FDA-approved drug to activate both GLP-1 and GIP receptors. Approved in May 2022 for type 2 diabetes, it quickly became one of the most-prescribed diabetes medications in the US and a major off-label tool for obesity. The same molecule is now sold as Zepbound for weight loss and sleep apnea.

Mounjaro activates GLP-1 receptors (appetite reduction, slowed gastric emptying, glucose-dependent insulin) and GIP receptors (additional insulin potentiation). The dual mechanism produces stronger A1c reduction and weight loss than GLP-1 alone.

Same as Zepbound: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg/week titration. Many diabetes patients find adequate A1c control at 5 or 10 mg.

SURPASS trials (type 2 diabetes): A1c reduction 1.9-2.6% at 15 mg, with average weight loss of 8-12 kg as a side benefit. Off-label weight-loss use shows similar results to Zepbound trials.

Same as Zepbound: nausea, diarrhea, constipation, vomiting, decreased appetite. Most GI effects improve after titration.

Mounjaro list price: $1,069/mo. Insurance coverage for diabetes is generally easier than for weight loss. Lilly savings card brings copay to $25/mo for commercially insured.

FDA-approved for adults with type 2 diabetes. Off-label use for weight loss is common but not insurance-covered under the diabetes indication unless type 2 diabetes is also documented.

Alternatives: Zepbound for weight-loss-only indication, Ozempic for diabetes (single-agonist), Trulicity for diabetes (different molecule).